Thanks, because if the Germans weren't being stingy then the opportunity to make a big portion of 100 grand a patient would be too much to resist, even at the cost of slow walking the Phase 3.
If revenue starts coming in the door you'll have an E for your P/E and that changes the whole conversation about the company and adds more credibility than announcing a hundred new trial sites in Canada or on Mars for that matter.